Global Ophthalmoplegia Market Size, Share, Forecast Report, 2020-2027

Ophthalmoplegia, also referred as extra ocular muscle palsy, is a paralysis of the extra ocular muscles that control movements of eyes. In this condition, nerve fibers that coordinate both eyes in horizontal movements looking from side to side- are damaged. A number of devices and treatments are available in the market, which can cure or improve the eyesight of the patient. The Global ophthalmoplegia market is driven by increasing number of people with ophthalmoplegia and increasing geriatric population. According to the World Health Organization in 2010, about 250 million people of over 50 years were suffering from visual impairment. Around 80% people in many of the developing countries have eye sight problems; of which nearly 50% of the people are not able to take treatment due to huge cost of the surgeries. Increasing prevalence of eye sight affecting diseases, for instance, diabetes and rapid developments in technology have fuelled the growth of the market. On the other hand, high cost of the treatment and availability of cheap alternative treatment may slow the growth of the market.
The global ophthalmoplegia market is expected to grow at a CAGR of ~ 7.2 % during the forecast period 2017-2023.
Segments
The global ophthalmoplegia market has been segmented on the basis of type, treatment and end user.

On the basis of types, the market is segmented into external ophthalmoplegia and internuclear ophthalmoplegia. External ophthalmoplegia is further segmented into superior recti, inferior recti, medial recti, lateral recti, inferior oblique, and superior oblique muscles.

On the basis of treatment, the market is segmented into surgery, drug treatment, and others. The surgery is further segmented into strabismus surgery and others.

On the basis of end users, the market is segmented into hospital & clinics, ambulatory clinics, and others.
Key Players
Some of key players profiled in the report are Abbott (US), Novartis AG (Switzerland), ZEISS International (Germany), Valeant Pharmaceuticals International, Inc. (US), Amritt, Inc. (US), Medline Industries, Inc. (US), ALLERGAN (Ireland), and Johnson & Johnson (US).